Assessment of Hepatitis C management on glycemic control among Type 2 Diabetes Mellitus patients

Abstract

Background: HCV and DM are chronic diseases of high global prevalence. Many studies proved the association between Hepatitis C and DM in the last three decades and this consists of an interrelated association; moreover, HCV infection triggers Diabetes Mellitus, most probably type 2. Objective: To assess the possibility of the improvement of T2DM in patients with HCV when applying the new DAA HCV treatment in Egypt. Patients and Methods:The current study is a prospective cohort hospital-based study that aims to describe the association between T2DM on one hand and chronic HCV on the other hand after successful management of HCV through the DAAs according to the protocol of the Ministry of Health. SVR was defined as undetectable HCV RNA levels at 12 weeks after the end of treatment (EOT). Fasting plasma glucose (FPG) levels between 100-125 mg/dL were defined as prediabetes and FPG ≥ 126 mg/dL was defined as diabetes. We have found positive correlation between management of HCV using DAAs in general and improvement of HbA1c and FPG. Moreover, we reported stronger correlation between achieving SVR and the HbA1c level and FPG. Results: After 12 weeks of follow-up, 82% of the patients maintained negative SVR, hemoglobin reduction was -0.6±0.4 %, 3 months after HCV treatment with a P value <0.001*. FPG reduction was -24.6±25.4 after 3 months of treatment with a P value of <0.001*. HbA1c reduction in patients with SVR was -0.8±0.2 % with a P value of <0.001*. No significant change in treatment choice was found during the period of study. Conclusion: Successful HCV eradication will result in a statistically significant reduction in fasting plasma glucose and HbA1c in patients with type 2 diabetes which is an indirect indicator of improvement of insulin sensitivity in patients with type 2 DM.

Prevalence of viral hepatitis (A, B, C, and E) infection and co-infection among hospitalized children in Cairo, Egypt

“…4 Recent research indicated that liver disease is the leading cause of death in Egypt, where mathematical models estimated a growth in the number of individuals with liver cirrhosis and liver cancer in the coming years. 4,5 Hepatitis C virus (HCV) and Hepatitis B virus (HBV) infections progress through three distinct phases. New infections (mostly asymptomatic but rarely symptomatic in the form of acute hepatitis) may progress into chronic infections (typically asymptomatic), which may develop into consequences such as cirrhosis and hepatocellular carcinoma (HCC) that result in morbidity and mortality.…”